104104-50-9 Usage
Description
SR-95531, also known as Gabazine Hydrobromide, is a derivative of γ-aminobutyric acid (GABA) that functions as a specific antagonist of GABAA receptors. It is characterized by its high affinity for these receptors (Ki = 74-150 nM) and its ability to induce seizures in mice when administered intravenously. SR-95531 is unique in that it selectively antagonizes GABA-induced chloride currents without affecting those induced by pentobarbitone. It has been shown to be effective against GABAA receptor isoforms from various species, including mice, rats, and humans.
Uses
Used in Pharmaceutical Industry:
SR-95531 is used as a research tool for studying the role of GABAA receptors in various neurological and psychiatric conditions. Its ability to selectively target these receptors without affecting other related enzymes, such as GABA-transaminase or glutamate-decarboxylase, makes it a valuable compound for investigating the underlying mechanisms of GABAergic signaling and its implications in health and disease.
Used in Neuroscience Research:
In the field of neuroscience, SR-95531 is employed as an antagonist to explore the function of GABAA receptors in the central nervous system. By blocking these receptors, researchers can gain insights into the effects of GABAergic inhibition on neuronal excitability, synaptic transmission, and overall brain function. This can help in understanding the role of GABAA receptors in cognitive processes, as well as in the development of potential therapeutic strategies for neurological disorders.
Used in Drug Development:
SR-95531 serves as a lead compound in the development of new drugs targeting GABAA receptors. Its high specificity and affinity for these receptors make it an attractive starting point for designing novel therapeutic agents that can modulate GABAergic signaling with greater precision. This could potentially lead to the development of more effective treatments for conditions such as epilepsy, anxiety, and certain neurodegenerative diseases, where GABAA receptor dysfunction has been implicated.
Used in Toxicology Studies:
Due to its ability to induce seizures in mice, SR-95531 is also utilized in toxicology research to investigate the potential neurotoxic effects of various substances on the central nervous system. By examining the interactions between SR-95531 and other compounds, researchers can assess the risk of seizure-inducing or neurotoxic effects associated with exposure to certain chemicals or drugs.
Biological Activity
Selective, competitive GABA A receptor antagonist. Displaces [ 3 H]-GABA from rat brain membranes with a K i of 150 nM. Unlike bicuculline, selectively antagonizes GABA-induced Cl - currents with little action on pentobarbitone-induced currents. Also acts as a low affinity glycine receptor antagonist.
Biochem/physiol Actions
SR-95531 is a specific GABAA receptor antagonist that does not affect GABA-transaminase or glutamate-decarboxylase activities.
Check Digit Verification of cas no
The CAS Registry Mumber 104104-50-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,0,4,1,0 and 4 respectively; the second part has 2 digits, 5 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 104104-50:
(8*1)+(7*0)+(6*4)+(5*1)+(4*0)+(3*4)+(2*5)+(1*0)=59
59 % 10 = 9
So 104104-50-9 is a valid CAS Registry Number.
InChI:InChI=1/C15H17N3O3.BrH/c1-21-12-6-4-11(5-7-12)13-8-9-14(16)18(17-13)10-2-3-15(19)20;/h4-9,16H,2-3,10H2,1H3,(H,19,20);1H/b16-14+;
104104-50-9Relevant articles and documents
Synthesis and Structure-Activity Relationships of Series of Aminopyridazine Derivatives of γ-Aminobutyric Acid Acting as Selective GABA-A Antagonists
Wermuth, Camille-Georges,Bourguignon, Jean-Jacques,Schlewer, Gilbert,Gies, Jean-Pierre,Schoenfelder, Angele,et al.
, p. 239 - 249 (2007/10/02)
We have recently shown that an aryloaminopyridazine derivarive of GABA, SR 95103 , is a selective and competitive GABA-A receptor antagonist.In order to further explore the structural requirements for GABA receptor affinity, we synthesized a series of 38 compounds by attaching various pyridazinic structures to GABA or GABA-like side chains.Most of the compounds displaced GABA from rat brain membranes.All the active compounds antagonized the GABA-elicited enhancement of diazepam binding, strongly suggesting that all these compounds are GABA-A receptor antagonists.None of the compounds that displaced GABA from rat brain membranes interacted with other GABA recognition sites (GABA-B receptor, GABA uptake binding site, glutamate decarboxylase, GABA-transaminase).They did not interact with the Cl- ionophore associated with the GABA-A receptor and did not interact with the benzodiazepine, strychnine, and glutamate binding sites.Thus these compounds appear to be specific GABA-A receptor antagonists.In terms of structure-activity, it can be concluded that a GABA moiety bearing a positive charge is necessary for optimal GABA-A receptor recognition.Additional binding sites are tolerated only if they are part of a charge-delocalized amidinic or guanidinic system.If this delocalization is achieved by linking a butyric acid moiety to the N(2) nitrogen of a 3-aminopyridazine, GABA-antagonistic character is produced.The highest potency (ca.250 times bicuculline) was observed when an aromatic ? system, bearing electron-donating substituents, was present on the 6-position of the pyridazine ring.
